首站-论文投稿智能助手
典型文献
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation
文献摘要:
Objective: Androgen deprivation therapy (ADT) is still the principal treatment option for prostate cancer (PCa). In addition to reactivation of androgen receptor signaling, the resistance of PCa to apoptosis during ADT also contributes to castration resistant PCa (CRPC). A previous study reported that gene transfer of IL-13Rα2 into PCa cells sensitized the cells to the IL-13R-targeted cytotoxin IL13Rα1, leading to apoptosis. Compared with IL-13Rα2, IL13Rα1 is more constitutively expressed in PCa cells, but its function in PCa remains to be established.Methods: We determined the role and expression of IL13Rα1 in PCa cancer cells using western blotting, flow cytometry, and cell proliferation assays. Co-immunoprecipitation and mass spectrometry were used to identify the proteins that interacted with IL13Rα1, to elucidate its function. Results: In this study, we showed that IL13Rα1 was selectively suppressed in androgen-deprived PCa cells and that its suppression tended to be associated with poor prognoses of PCa patients. IL13Rα1 overexpression promoted apoptosis and inhibited tumor growth under androgen-deprived or castrated conditions (P < 0.01). Mechanistically, IL13Rα1 recruited and facilitated ubiquitin protein ligase E3C-mediated ubiquitination and degradation of hexokinase 2 (HK2), resulting in glycolytic inhibition and eventually leading to PCa cell apoptosis. Furthermore, our data revealed that mutated ataxia-telangiectasia kinase phosphorylated and facilitated the selective ubiquitin proteasome-mediated degradation of HK2. Notably, IL13Rα1-overexpressing PCa cells were more susceptible to apoptosis and exhibited reduced tumor growth after exposure to the HK2 inhibitor, 2-deoxy-D-glucose (P < 0.01). Conclusions: Our data identified a tumor suppressor role for IL13Rα1 in preventing the resistance of PCa cells to apoptosis during androgen deprivation by inhibiting glycolysis. IL13Rα1-mediated signaling involving HK2 may therefore provide a novel treatment target and strategy for CRPC.
文献关键词:
作者姓名:
Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang
作者机构:
Department of Pathology,School of Basic Medical Sciences,Shandong University,Jinan 250012,China;Department of Pathology,The Fourth People's Hospital of Jinan,Jinan 250031,China;Department of PET-CT,Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of Medical Sciences,Jinan 250002,China;The Second Hospital,Cheeloo College of Medicine,Shandong University Medical School,Jinan 250012,China;Biomedical Sciences College&Shandong Medicinal Biotechnology Centre,Key Lab for Biotech-Drugs of National Health Commission,Key Lab for Rare&Uncommon Diseases of Shandong Province,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Biochemistry and Molecular Biology,Shandong University School of Basic Medical Sciences,Jinan 250012,China;Institute of Basic Medicine,Shandong Academy of Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250002,China;Department of Oncology,The First Affiliated Hospital of Shandong First Medical University,Jinan 250014,China
引用格式:
[1]Tingting Feng;Jing Wang;Kai Cheng;Qiqi Lu;Ru Zhao;Shiguan Wang;Qingyun Zhang;Luna Ge;Jihong Pan;Guanhua Song;Lin Wang-.IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation)[J].癌症生物学与医学(英文版),2022(07):1008-1028
A类:
IL13R,13R,castrated,E3C
B类:
prevents,castration,resistant,phenotype,prostate,cancer,by,targeting,hexokinase,mediated,degradation,Objective,Androgen,deprivation,therapy,ADT,still,principal,treatment,option,PCa,In,addition,reactivation,androgen,receptor,signaling,resistance,apoptosis,during,also,contributes,CRPC,previous,study,reported,that,gene,transfer,into,cells,sensitized,targeted,cytotoxin,leading,Compared,constitutively,expressed,its,function,remains,be,established,Methods,We,determined,role,using,western,blotting,flow,cytometry,proliferation,assays,immunoprecipitation,mass,spectrometry,were,used,identify,proteins,interacted,elucidate,Results,this,showed,was,selectively,suppressed,deprived,suppression,tended,associated,poor,prognoses,patients,overexpression,promoted,inhibited,tumor,growth,under,conditions,Mechanistically,recruited,facilitated,ligase,ubiquitination,HK2,resulting,glycolytic,inhibition,eventually,Furthermore,our,data,revealed,mutated,ataxia,telangiectasia,phosphorylated,proteasome,Notably,overexpressing,susceptible,exhibited,reduced,after,exposure,inhibitor,deoxy,glucose,Conclusions,Our,identified,suppressor,preventing,inhibiting,glycolysis,involving,may,therefore,provide,novel,strategy
AB值:
0.503424
相似文献
Paired box 5 increases the chemosensitivity of esophageal squamous cell cancer cells by promoting p53 signaling activity
Zhang Weiwei;Yan Wenji;Qian Niansong;Han Quanli;Zhang Weitao;Dai Guanghai-Chinese People’s Liberation Army Medical School, Beijing 100853, China;Department of the Third Health Care, The Second Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, China;Department of Oncology, The Hainan Medical Center, Chinese People’s Liberation Army General Hospital, Sanya 572022, China;Cancer Center, Beijing Tongren Hospital Affiliated to Capital Medical University, Economic and Technological Development Zone, Beijing 100176, China
Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+T cell-mediated ferroptosis in castration-resistant prostate cancer
Xumin Zhou;Libin Zou;Hangyu Liao;Junqi Luo;Taowei Yang;Jun Wu;Wenbin Chen;Kaihui Wu;Shengren Cen;Daojun Lv;Fangpeng Shu;Yu Yang;Chun Li;Bingkun Li;Xiangming Mao-Department of Urology,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Second Department of Hepatobiliary Surgery,Zhujiang Hospital,Southern Medical University,Guangzhou 510280,China;Department of Urology,Minimally Invasive Surgery Center,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou 510120,China;Department of Urology,Guangzhou Women and Children's Medical Center,Guangzhou Medical University,Guangzhou 510623,China;Department of Urology,Peking University Shenzhen Hospital,Shenzhen 518036,China;Nursing Department,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China
Mannose inhibits the growth of prostate cancer through a mitochondrial mechanism
Yu-Lin Deng;Ren Liu;Zhou-Da Cai;Zhao-Dong Han;Yuan-Fa Feng;Shang-Hua Cai;Qing-Biao Chen;Jian-Guo Zhu;Wei-De Zhong-Guangdong Provincial Institute of Nephrology,Nanfang Hospital,Southern Medical University,Guangzhou 510515,China;Department of Andrology,Guangzhou First People's Hospital,School of Medicine,South China University of Technology,Guangzhou 510180,China;Department of Urology,Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics,Guangzhou First People's Hospital,School of Medicine,South China University of Technology,Guangzhou 510180,China;Urology Key Laboratory of Guangdong Province,The First Affiliated Hospital of Guangzhou Medical University,Guangzhou Medical University,Guangzhou 510230,China;Department of Urology Surgery,Affiliated Foshan Hospital of Southern Medical University,Foshan 528000,China;Department of Urology,Guizhou Provincial People's Hospital,The Affiliated Hospital of Guizhou Medical University,Guiyang 550002,China
Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays
Jin-ping Pang;Chao Shen;Wen-fang Zhou;Yun-xia Wang;Lu-hu Shan;Xin Chai;Ying Shao;Xue-ping Hu;Feng Zhu;Dan-yan Zhu;Li Xiao;Lei Xu;Xiao-hong Xu;Dan Li;Ting-jun Hou-Hangzhou Institute of Innovative Medicine,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China;Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences,Cancer Hospital of University of Chinese Academy of Sciences,Zhejiang Cancer Hospital,Hangzhou 310022,China;School of Life Science,Huzhou University,Huzhou 313000,China;Institute of Bioinformatics and Medical Engineering,School of Electrical and Information Engineering,Jiangsu University of Technology,Changzhou 213001,China;State Key Lab of CAD&CG,Zhejiang University,Hangzhou 310058,China
Stratifin promotes renal dysfunction in ischemic and nephrotoxic AKI mouse models via enhancing RIPK3-mediated necroptosis
Fang Wang;Jia-nan Wang;Xiao-yan He;Xiao-guo Suo;Chao Li;Wei-jian Ni;Yu-ting Cai;Yuan He;Xin-yun Fang;Yu-hang Dong;Tian Xing;Ya-ru Yang;Feng Zhang;Xiang Zhong;Hong-mei Zang;Ming-ming Liu;Jun Li;Xiao-ming Meng;Juan Jin-Inflammation and Immune Mediated Diseases Laboratory of Anhui Province,Anhui Institute of Innovative Drugs,School of Pharmacy,Anhui Medical University,The Key Laboratory of Anti-inflammatory of Immune Medicines,Ministry of Education,Hefei 230032,China;Department of Pharmacy,Anhui Provincial Hospital,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China;Hospital of Stomatology,Anhui Medical University,Key Laboratory of Oral Diseases Research of Anhui Province,Hefei 230032,China;Department of Pharmacy,Changzheng Hospital,Naval Medical University,Shanghai 200003,China;Department of Nephrology,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,China;School of Basic Medical Sciences,Anhui Medical University,Hefei 230032,China
The novel indomethacin derivative CZ-212-3 exerts antitumor effects on castration-resistant prostate cancer by degrading androgen receptor and its variants
Hong Wang;Zhe Chang;Guo-di Cai;Ping Yang;Jiang-he Chen;Shan-shu Yang;Yin-feng Guo;Ming-yu Wang;Xue-hua Zheng;Jin-ping Lei;Pei-qing Liu;De-peng Zhao;Jun-jian Wang-School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China;State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China;Department of Pathology,Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Key Laboratory of Molecular Target and Clinical Pharmacology,School of Pharmaceutical Sciences and the Fifth Affiliated Hospital,Guangzhou Medical University,Guangzhou 510006,China;Guangdong Provincial Key Laboratory of New Drug Design and Evaluation,School of Pharmaceutical Sciences,Sun Yat-sen University,Guangzhou 510006,China;National-Local Joint Engineering Laboratory of Druggability and New Drugs Evaluation,Sun Yat-sen University,Guangzhou 510006,China
Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment
Da-cai Xu;Li Yang;Pei-quan Zhang;Ding Yan;Qian Xue;Qing-tian Huang;Xiao-fen Li;Ya-li Hao;Dao-lin Tang;Q.Ping Dou;Xin Chen;Jin-bao Liu-Affliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China;Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation,School of Basic Medical Sciences,Guangzhou Medical University,Guangzhou 511436,China;The Department of Physiology,School of Basic Medical Sciences,Guizhou Medical University,Guiyang 550003,China;Department of Surgery,UT Southwestern Medical Center,Dallas,TX 75390,USA;Barbara Ann Karmanos Cancer Institute and Departments of Oncology,Pharmacology&Pathology,School of Medicine,Wayne State University,Detroit,MI 48201,USA
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。